Kali Stasi

Company: SalioGen Therapeutics

Job title: Chief Medical Officer

Seminars:

Roundtable: Navigating Phase 2 Trials: Ensuring Safety & Efficacy in Gene Therapy for Ophthalmic Disorders 11:00 am

Exploring the intricate balance between safety and efficacy assessments in phase 2 trials for gene therapy interventions targeting ophthalmic disorders Addressing the unique hurdles faced in validating safety parameters and defining efficacy endpoints, particularly in slowly progressive diseases characteristic of ophthalmic disorders Strategies for seamless transition from phase 2 to phase 3 trials, emphasizing the…Read more

day: Day Two 12th